Physician profile
Tri Minh Pham
NPI 1831205707
$6,177.91
in general payments reported to CMS, 2019-2025
41 companies · $546 in 2025
The $546 reported for 2025 was more than what 75% of Internal Medicine providers received nationally (typical 2025 total: $156).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,297 · 2020: $899 · 2021: $1,101 · 2022: $1,128 · 2023: $459 · 2024: $749 · 2025: $546.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,737 · Education: $16.88.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,736.96 |
| Education | $16.88 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astrazeneca Pharmaceuticals LP | $1,344.65 | 2019-2025 | Farxiga, Breztri, Airsupra |
| Novo Nordisk INC | $699.02 | 2019-2025 | Ozempic, Rybelsus |
| Bayer Healthcare Pharmaceuticals INC. | $485.41 | 2021-2025 | |
| Lilly USA, LLC | $412.30 | 2019-2025 | Mounjaro, Zepbound, Jardiance |
| Boehringer Ingelheim Pharmaceuticals, INC. | $314.13 | 2019-2025 | Jardiance |
| Pfizer INC. | $267.90 | 2019-2023 | |
| Merck Sharp & Dohme LLC | $242.31 | 2019-2023 | Verquvo, Steglatro, Belsomra |
| Ucb, INC. | $239.06 | 2020-2024 | Nayzilam, Briviact |
| Novartis Pharmaceuticals Corporation | $209.10 | 2019-2022 | |
| Amarin Pharma, INC. | $164.48 | 2019-2022 | |
| Amgen INC. | $163.54 | 2019-2025 | Repatha, Otezla, Repatha |
| Astellas Pharma US INC | $141.52 | 2020-2025 | Veozah |
| Teva Pharmaceuticals USA, INC. | $138.60 | 2019 | |
| Janssen Pharmaceuticals, INC | $133.45 | 2020-2023 | Xarelto |
| Abbvie INC. | $114.25 | 2021-2024 |
Show all 41 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Tri Pham listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.